{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:30:13Z","timestamp":1792132213299,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalofnuclearcardiology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.nuclcard.2025.102573","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:01:32Z","timestamp":1764230492000},"page":"102573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Artificial intelligence\u2013driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-2433","authenticated-orcid":false,"given":"Robert JH.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5199-3071","authenticated-orcid":false,"given":"Aakash","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Shahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Bosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damini","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-9578","authenticated-orcid":false,"given":"Daniel S.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-938X","authenticated-orcid":false,"given":"Piotr J.","family":"Slomka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nuclcard.2025.102573_bib1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis: a novel imaging biomarker","volume":"13","author":"Scully","year":"2020","journal-title":"JACC, Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2025.102573_bib3","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis","volume":"28","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib4","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s12350-021-02806-4","article-title":"Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis","volume":"29","author":"Roshankar","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2967\/jnumed.124.267542","article-title":"Deep learning-enabled quantification of (99m)Tc-Pyrophosphate SPECT\/CT for cardiac amyloidosis","volume":"65","author":"Miller","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2025.102573_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2025.102573_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2025.102573_bib8","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2025.102573_bib9","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.nuclcard.2025.102573_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102019","article-title":"Quantitative (99m)Tc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy","volume":"39","author":"Vijayakumar","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis","volume":"27","author":"Dorbala","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial Pericardial Disease","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nuclcard.2025.102573_bib13","first-page":"2566","article-title":"Factors influencing clinical initiation of tafamidis therapy for transthyretin amyloidosis cardiomyopathy: a Canadian referral center experience","volume":"40","author":"Shahi","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib14","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/ejhf.3354","article-title":"Expansion of the national amyloidosis centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nuclcard.2025.102573_bib15","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/jmri.22753","article-title":"Myocardial T1 mapping with MRI: comparison of look-locker and MOLLI sequences","volume":"34","author":"Nacif","year":"2011","journal-title":"J Magn Reson Imag"},{"key":"10.1016\/j.nuclcard.2025.102573_bib16","doi-asserted-by":"crossref","first-page":"O27","DOI":"10.1186\/1532-429X-17-S1-O27","article-title":"LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study","volume":"17","author":"Fontana","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.nuclcard.2025.102573_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/hc0402.102975","article-title":"Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart","volume":"105","author":"Cerqueira","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.nuclcard.2025.102573_bib18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/jmri.24116","article-title":"Validation of sub-segmental visual scoring for the quantification of ischemic and nonischemic myocardial fibrosis using late gadolinium enhancement MRI","volume":"38","author":"Fine","year":"2013","journal-title":"J Magn Reson Imag"},{"key":"10.1016\/j.nuclcard.2025.102573_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-8-1","article-title":"An administrative data merging solution for dealing with missing data in a clinical registry: adaptation from ICD-9 to ICD-10","volume":"8","author":"Southern","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials","volume":"66","author":"Hicks","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib21","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2025.102573_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2025.102573_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.015243","article-title":"Gene silencing therapy in hereditary (Variant) transthyretin cardiac amyloidosis: a puzzling case of decreasing pyrophosphate uptake on scintigraphy","volume":"16","author":"Smiley","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2025.102573_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030512","article-title":"Use of Technetium-99m-Pyrophosphate single-photon emission computed tomography\/computed tomography in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin amyloid cardiomyopathy","volume":"13","author":"Yu","year":"2024","journal-title":"JAHA"},{"key":"10.1016\/j.nuclcard.2025.102573_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102056","article-title":"Single-photon emission computed tomography\/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis","volume":"42","author":"Godoy-Rivas","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/13506129.2023.2247136","article-title":"Reduction in (99m)Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy","volume":"31","author":"Rettl","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2025.102573_bib27","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1093\/eurheartj\/ehaf412","article-title":"Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance","volume":"46","author":"Patel","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nuclcard.2025.102573_bib28","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib29","first-page":"189","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC: Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2025.102573_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.101809","article-title":"Deep learning approach for automated segmentation of myocardium using bone scintigraphy single-photon emission computed tomography\/computed tomography in patients with suspected cardiac amyloidosis","volume":"33","author":"Bhattaru","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2025.102573_bib31","first-page":"1085","article-title":"Deep learning on bone scintigraphy to detect abnormal cardiac uptake at risk of cardiac amyloidosis","volume":"16","author":"Delbarre","year":"2023","journal-title":"JACC: Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2025.102573_bib32","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2589-7500(23)00265-0","article-title":"Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study","volume":"6","author":"Spielvogel","year":"2024","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.nuclcard.2025.102573_bib33","article-title":"Cardiac uptake of 124I-Evuzamitide in PET\/CT images correlates with echocardiographic parameters and can be used for monitoring changes in systemic amyloid load","volume":"65","author":"Martin","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2025.102573_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010249","article-title":"Efficient 1-Hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis","volume":"13","author":"Masri","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2025.102573_bib35","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"EHJ Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2025.102573_bib36","article-title":"Development and initial results from the Canadian cardiac amyloidosis PyrophosphatE imaging registry (CAPER)","author":"Akincioglu","year":"2025","journal-title":"Can J Cardiol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358125004477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358125004477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:20:55Z","timestamp":1781238055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358125004477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"alternative-id":["S1071358125004477"],"URL":"https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102573","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial intelligence\u2013driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology.","name":"copyright","label":"Copyright"}],"article-number":"102573"}}